BEGIN:VCALENDAR
VERSION:2.0
PRODID:Linklings LLC
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
X-LIC-LOCATION:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:19700308T020000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=2SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:19701101T020000
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTAMP:20241017T183512Z
LOCATION:Harbor Ballrooms D-I
DTSTART;TZID=America/Los_Angeles:20241016T114000
DTEND;TZID=America/Los_Angeles:20241016T120000
UID:ncs_NCS 2024_sess125_ccrnt151@linklings.com
SUMMARY:Novel Therapeutic Strategy to Modulate CNS Neuroinflammation and P
 romote Functional recovery in Traumatic Brain Injury
DESCRIPTION:Breakout Session\n\nSaef Izzy (Brigham and Women's Hospital, H
 arvard Medical School)\n\nTraumatic brain injury (TBI) is a leading cause 
 of disability in the United States. Current treatments have focused on ear
 ly surgical intervention to limit hematoma expansion and supportive therap
 y; however, there are limited pharmacological interventions to reduce long
 -term cognitive sequelae post-injury. TBI causes a primary injury followed
  by a secondary biochemical and cellular response, which involves the indu
 ction of the neuroinflammatory response, which has been shown to contribut
 e to worsening neurological outcomes after injury. The investigations in T
 BI have been hampered by the lack of effective immunotherapeutics that cou
 ld target microglia (brain resident cells) inflammation and improve outcom
 es after injury. The mucosal immune system is a unique tolerogenic organ t
 hat provides a physiological approach for the induction of regulatory T ce
 lls (Tregs). Tregs were found to alleviate the inflammatory response by in
 hibiting microglial inflammation in preclinical TBI studies. Yet, there ar
 e still no effective and safe therapies capable of inducing Tregs and impr
 oving outcomes after TBI. In this talk, we will report that inducing immun
 e tolerance by targeting nasal mucosa via anti-CD3 is a safe and novel the
 rapeutic approach associated with CNS immune modulation and improvement in
  long-term behavioral outcomes after injury. Our studies have immediate tr
 anslational possibilities for treating TBI patients given that a fully hum
 anized anti-CD3 mAb (Foralumab) has been given to healthy volunteers and h
 as shown positive effects in a pilot study of subjects suffering from COVI
 D-19. The content to be presented in this talk has been supported by an NC
 S Research Training Fellowship.\n\nTrack: Science of Neurocritical Care\n\
 nFocus Area: Informatics, Nursing Pharmacology, Traumatic Brain Injury\n\n
 Target Audience: Advanced\n\nSession Chair: Molly McNett (The Ohio State U
 niversity)
END:VEVENT
END:VCALENDAR